(MedPage Today) — Finerenone (Kerendia) significantly reduced albuminuria in adults with type 1 diabetes and chronic kidney disease (CKD), meeting the primary endpoint of the phase III FINE-ONE trial.
Over 6 months, the urinary albumin-to-creatinine…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
